Brain tumour clinical trial title
Biomede – Biological Medicine for Diffuse Intrinsic Pontine Glioma (study ID: 33023)
Brain tumour type
Glioma,
Website
www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-targeted-cancer-therapies-for-children-and-young-people-with-a-brain-tumour-biomede
Description:
Biomede is an international, multicenter, randomised, open-label, adaptive, phase II trial of treatment for Diffuse Intrinsic Pontine Glioma (DIPG). This trial mandates a biopsy of the tumour to obtain the biological profile of the tumour. The allocation of treatment in each patient will be based on the specific biological tumour profile. Recruitment target is 80 patients in the UK, 250 in the EU with DIPG over 4 years. The initial agents to be studied based on biomarkers profile are; Dasatinib, Erlotinib and Everolimus as single agents combined with standard radiotherapy.
Date added:
12th January 2019
Open/Closed:
Open
Trial ends:
April 2021
Provider
Institute of Cancer Research
Contact details